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A b s t r a c t 
Background: Left bundle branch block (LBBB) is an important qualification criterion and determinant of prognosis in cardiac 
resynchronisation therapy (CRT) patients. 
Aim: Our goal was to investigate the long-term mortality and morbidity in a sizable cohort of patients with CRT with regard 
to the new strict LBBB definition proposed by Perrin.
Methods: We performed a longitudinal cohort study that included consecutive CRT patients. Primary endpoint (all-cause 
death) and secondary endpoint (all-cause death and hospitalisation for heart failure) were analysed. All preimplantation elec-
trocardiograms were categorised as LBBB or non-LBBB according to the new definitions/criteria analysed.
Results: The survival analysis comprised 552 patients with CRT. The Perrin criteria, CRT guidelines class I indication criteria, 
and Strauss criteria were fulfilled in 38.9%, 79.4%, and 62.3% of all LBBB patients, respectively. During the nine-year study 
period, 232 patients died and the combined endpoint was met by 292 patients. The Perrin “true LBBB” definition criteria 
were inferior to the Strauss “complete” LBBB definition criteria in predicting survival as reflected by Kaplan-Meier survival 
curves (C-statistics). Multivariate Cox regression models showed that both LBBB definitions predicted mortality, however, the 
Perrin definition had a higher hazard ratio (HR 0.67) compared to the Strauss definition (HR 0.51).
Conclusions: It seems that the Perrin “true LBBB” criteria are not well-suited for the selection of CRT candidates. Perhaps they 
do not reflect the presence of a true/complete LBBB or exclude too many patients who, despite some residual conduction in 
the left bundle branch, responded well to CRT.
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INTRODUCTION
Cardiac resynchronisation therapy (CRT) improves heart fail-
ure (HF)-related symptoms and long-term outcome in chronic 
HF patients, mainly by correcting the delayed contraction of 
the lateral segments of the left ventricle induced by left bun-
dle branch block (LBBB). Several clinical echocardiographic 
and electrocardiographic parameters predict the long-term 
outcome in CRT [1–6]. The prognostic importance of LBBB in 
patients scheduled for CRT has been especially well-studied in 
the past [7, 8]. However, conflicting results have made clinical 
recommendations uncertain. In some studies, patients with 
an LBBB morphology had better outcomes than patients with 
a non-LBBB morphology [8–10]. In other studies, no clinical 
difference or even a worse clinical prognosis was seen in pa-
tients with LBBB [11, 12]. However, in CRT studies, several 
substantially different electrocardiographic criteria for LBBB 
have been used. We and others have shown the importance of 
LBBB definition/criteria in predicting long-term mortality and 
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morbidity in CRT patients, which might explain the divergent 
results of the clinical studies regarding the impact of LBBB on 
CRT outcome and help to formulate an optimal LBBB defini-
tion for CRT candidate selection [13, 14].
Recently, two new definitions were proposed with the in-
tention to identify “complete” or “true” LBBB — theoretically, 
an optimal substrate for cardiac resynchronisation. Strauss et 
al. [15, 16], on the basis of pathophysiological data, proposed 
that the “complete LBBB” definition should include a longer 
QRS duration (> 130 ms in women and > 140 ms in men) and 
the presence of at least two mid-QRS notches/slurs in leads 
I, aVL, V1, V2, V5, or V6. Padanilam et al. [17] analysed the QRS 
morphology of patients with electrophysiologically-confirmed 
total LBBB without any residual conduction and concluded 
that an R wave ≥ 1 mm in V1 points to an incomplete LBBB. 
On the basis of that study, Perrin et al. [18] proposed a new 
“true LBBB” definition that included the obligatory lack of 
hypothetical markers of residual left to right conduction, i.e. 
no R wave ≥ 1 mm in V1 and no Q wave ≥ 1 mm in aVL. 
Examples of QRS morphologies that fit these two new LBBB 
definitions are presented in Figure 1. The Strauss definition 
was clinically validated by two large studies (Jastrzębski et al. 
[13] and Caputo et al. [14]) which showed better long-term 
survival of CRT patients when the “complete LBBB” definition 
was fulfilled. Other studies which assessed “soft” endpoints, 
such as better echocardiographic or clinical response [19, 20], 
also supported the Strauss definition as being more suitable 
for LBBB diagnosis in CRT candidates. In contrast, the “true 
LBBB” definition by Perrin et al. [18] was validated only by 
the PREDICT study sub-analysis, which was limited to the as-
sessment of short-term echocardiographic response. Neither 
long-term mortality/morbidity analysis nor “head-to-head” 
comparison with the other new stricter LBBB definition is 
available for the Padanilam/Perrin criteria.
Our aim was to assess, in a sizable cohort of CRT patients, 
the “true LBBB” definition as proposed by Perrin, with regard 
to the long-term mortality and morbidity, and run a compari-
son to the Strauss LBBB definition and to the QRS morphology 
compliant with the current class I CRT indications according 
to the recognised guidelines.
METHODS
Study group and outcome endpoints
Patients who received CRT at our institution in the period from 
mid-2006 to the end of 2014 were included in this retrospec-
tive analysis. Relevant clinical data and pertinent procedural 
Figure 1. Examples of 12-lead electrocardiograms (ESCs) that fulfil different left bundle branch block (LBBB) criteria. A1, A2. Two 
examples of LBBB according to Padanilam/Perrin but not according to Strauss (only a single QRS with slur/notch) and not ful- 
filling the European Society of Cardiology (ESC) guidelines class I indications for cardiac resynchronisation therapy (CRT) 
(QRS < 150 ms); B1. LBBB according to Strauss definition and fulfilling the ESC CRT guidelines class I criteria but a non-LBBB  
morphology according to Perrin (r in V1 ≥ 1 mm); B2. LBBB according to Strauss definition but neither fulfilling the ESC CRT  
guidelines class I criteria (QRS < 150 ms) nor the LBBB criteria according to Perrin (r in V1 and q in aVL ≥ 1 mm and no R/qR in aVL);  
C1, C2. ECGs indicating LBBB according to the ESC CRT guidelines class I/level A indications for CRT but categorised as non-LBBB 
according to both Perrin (q in aVL ≥ 1 mm in C1 and r in V1 ≥ 1 mm in C2) and Strauss LBBB definitions (lack of two QRS  
complexes in I, aVL, V1–V2, V5–V6 with a notch/slur)
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data were obtained from patient medical records. Endpoint 
data (deaths and hospitalisations) were obtained during out-
patient follow-up visits (most of our patients routinely visit 
our clinic for diagnostic check-ups) or telephone interviews 
with patients or their family members. If the patients could 
not be contacted (directly or indirectly), the national PESEL 
registry was used to check the dead or alive status. Two end-
points were analysed: primary — all-cause mortality/heart 
transplantation and secondary — HF hospitalisation or death 
from any cause.
Electrocardiographic data
Continuous 12-lead preimplantation electrocardiograms 
(ECGs) were recorded on an electrophysiological system 
(BARD LabSystems Pro, Boston Scientific, Boston, MA, USA) 
in all patients undergoing CRT device implantation. Both QRS 
duration and R wave peak delay in V6 were measured using 
a global method. R wave peak delay was measured from the 
earliest onset of QRS in all 12 leads on a standard ECG to 
the R wave peak in V6, as recommended by the American 
Heart Association (AHA) and the World Health Organisation 
(WHO) [21, 22]. ECG tracings were analysed by two physi-
cians blinded to the outcome of the study according to three 
different criteria sets: the Strauss LBBB definition, the Perrin 
definition, and the European Society of Cardiology (ESC) 
guidelines class I/level of evidence A indications for CRT 
[23]. The Strauss LBBB definition was based on the original 
publication with a later modification which removed the 
requirement that the leads with notch/slur be “contiguous.” 
The Perrin definition, as provided in the original publication, 
was based on the AHA LBBB definition with the added extra 
Padanilam/Perrin criteria. The ECS guidelines do not specify 
any LBBB definition; therefore, the guideline criteria in this 
study were based on the conventional LBBB definition based 
on V1 and V6 morphology with an added requirement of QRS 
duration > 150 ms. The three sets of criteria/definitions are 
summarised in Table 1. 
Any disparity in classifying patients as having LBBB or 
non-LBBB morphology were solved by reaching consensus 
between the two researchers or through consulting a third 
investigator when necessary. Measurements were taken using 
precise interval measurements and morphology assessment on 
the electrophysiological system with high signal augmentation 
and a sweep speed of 100 mm/s. 
A non-specific intraventricular conduction delay (NIVCD) 
was diagnosed when the QRS was ≥ 120 ms and the criteria for 
diagnosis of LBBB or right bundle branch block were not met. 
Statistical analysis
Continuous variables are presented as mean and standard 
deviation while categorical variables are presented as num-
ber and percentage. Kaplan-Meier curves were generated to 
trace the survival of each study endpoint. The discriminative 
power of a single LBBB definition was obtained using Har-
rell’s C-statistic. C-statistic values were compared in order 
to determine which LBBB definition was better at predicting 
survival. Cox proportional hazards (CPH) models were then 
used to determine the impact of LBBB on survival after adjust-
ing for potential confounders. Variables that were deemed 
to have clinical relevance were preselected and entered into 
the multivariate CPH models. Results of these models are 
presented as hazard ratios (HRs) and 95% confidence intervals 
(CIs). The proportionality assumption required for the CPH 
method was met. All statistical analyses were performed using 
Table 1. Criteria included in the two new definitions of left bundle branch block (LBBB) and the European Society of Cardiology 
(ECS) class I indications for cardiac resynchronisation therapy (CRT) 
Perrin:  
“True LBBB”
Strauss:  
“Complete LBBB” 
ESC CRT guidelines 
Class I
QRS ≥ 120 ms +
QRS ≥ 130 ms (female)
QRS ≥ 140 ms (male) +
QRS ≥ 150 ms +
R peak > 60 ms in V5/V6 + +
rS or QS in V1/V2 (with R peak time < 60 ms) + + +
Monophasic R in I +
Monophasic R or qR in aVL +
Notched or slurred R in ≥ 1 lead: I, aVL, V5, V6* +
Mid-QRS notch or slur in ≥ 2 leads: I, aVL, V1, V2, V5, V6 +
No Q wave in I, V5, V6 +
No Q wave ≥ 1 mm in aVL and no R wave ≥ 1 mm in V1 +
*The notch/slur does not have to be “mid-QRS”
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the R 3.2 software (the R Foundation for Statistical Computing, 
Vienna, Austria) with p-values < 0.05 considered statisti-
cally significant.
RESULTS
Population and implant results
The inclusion criteria were met by 590 patients who under-
went CRT device implantation during the previously specified 
study period. Of these, 38 patients were excluded: 15 due to 
an unsuccessful left ventricular (LV) lead implantation (a suc-
cess rate of 97.5%), eight due to incomplete medical records, 
five due to a late LV lead repositioning/loss of CRT, seven due 
to a necessary upgrade to triple-site pacing (two LV leads), 
and three due to the usage of a non-standard resynchronisa-
tion approach (i.e. direct His bundle pacing, dual-site right 
ventricular pacing). As a result, 552 patients were left in the 
dataset. Baseline clinical characteristics, the presence or ab-
sence of LBBB, and the outcomes of CRT device implantation 
are presented in Table 2.
ECG categorisation according  
to LBBB definitions
According to the conventional definition of LBBB (rS/QS 
morphology in V1 and R peak in V6 ≥ 60 ms, QRS ≥ 120 ms), 
350 (63.4%) patients had LBBB, 52 (9.4%) had NIVCD, 
31 (5.6%) had right bundle branch block, 98 (17.7%) had 
paced QRS, and 21 (3.8%) had a narrow QRS. The Perrin and 
Strauss definitions and the CRT ESC guideline criteria were 
fulfilled in 136 (24.6%), 218 (39.5%), and 278 (50.4%) of all 
patients, respectively, and in 38.9%, 62.3%, and 79.4% of 
patients with LBBB according to the conventional definition.
During the nine-year investigatory period, 232 patients 
met the primary endpoint of death from any cause (n = 228) 
or urgent heart transplantation (n = 4). The survival rates at 
the end of years one to seven were 89.7%, 80.7%, 70.6%, 
63.6%, 57.2%, 52.7%, and 46.9%, respectively. During this 
same period, 128 patients were hospitalised for an exacer-
bation of HF symptoms and 68 of these patients eventually 
died. Consequently, 292 patients met the combined second-
ary endpoint of all-cause mortality or hospitalisation for HF 
(232 patients who died and 60 patients who had HF exacer-
bations but survived).
Kaplan-Meier curves for the two study endpoints with 
regard to the Perrin definition, CRT guidelines, and Strauss 
criteria are presented in Figure 2. C-statistics for the Perrin 
definition, CRT guidelines criteria, and Strauss criteria for 
all-cause mortality were 0.547 (p = 0.004), 0.542 (p = 0.036), 
and 0.581 (p < 0.001), respectively, and for the secondary 
combined endpoint of all-cause mortality and HF hospitalisa-
tion they were 0.557 (p < 0.001), 0.553 (p = 0.003), and 
0.581 (p < 0.001), respectively. The comparison of C-statistics 
showed that the Padanilam/Perrin definition was inferior to the 
Strauss definition for predicting all-cause mortality (p = 0.039) 
but not for predicting the secondary combined endpoint of 
all-cause mortality and HF hospitalisation (p = 0.101); no dif-
ferences in C-statistics between Perrin and ESC CRT guidelines 
class I criteria were present for the primary (p = 0.745) or 
secondary endpoint (p = 0.985).
Multivariate Cox HRs for the three LBBB definitions/crite-
ria, including other pertinent clinical variables, are presented 
in Tables 3 and 4. The presence of LBBB according to the Per-
rin definition was associated with all-cause mortality and the 
combined end-point of all-cause mortality and hospitalisation 
for HF. Prognostic value of the Perrin definition was similar to 
the prognostic value of the ECS CRT guidelines criteria and 
lower than the prognostic importance of the Strauss definition.
DISCUSSION
To our best knowledge, this is the largest cohort study with 
the longest follow-up to date that examines the new “true 
LBBB” definition proposed by Perrin et al. [18]. The major 
finding of the current study is that the Perrin definition 
seems less useful for the prediction of outcome in CRT pa-
tients. Firstly, the Perrin definition was much more exclusive 
because it was fulfilled by only 38.9% of all LBBB patients, 
whereas the Strauss definition and ESC CRT guidelines class I 
QRS morphology criteria were met by 62.3% and 79.4% of 
patients, respectively. This is an unfavourable characteristic 
for the potential use for CRT patient selection. Based on the 
known non-responder rate of approximately 30%, it can 
be speculated that an optimal LBBB definition should not 
exclude more than 30% of patients with LBBB morphology. 
Secondly, the absolute difference in all-cause mortality at six 
years between patients with and without LBBB according to 
this definition was 11%, which was much less than the 20% 
difference seen when the Strauss definition was applied. This 
was also reflected by the significant difference in C-statistics 
between these two LBBB definitions. Results for the combined 
endpoint of all-cause mortality and HF hospitalisations were 
very similar. 
A possible explanation for the observed findings is that the 
R wave ≥ 1 mm in V1 is, after all, not a marker for left-to-right 
ventricular septum activation that indicates residual conduc-
tion over the left bundle branch. Wellens [24] suggests that 
larger R waves in V1 might result from unopposed activation of 
the free wall of the right ventricle, which produces an activa-
tion vector directed at lead V1. Such a situation takes place in 
patients with LBBB and after a large anteroseptal myocardial 
infarction that causes the absence or diminished right-to-left 
activation of the interventricular septum.
Another possible explanation is that the presence of 
residual LBBB conduction is not important from the perspec-
tive of mechanistic paradigm behind CRT. Probably, when 
the Strauss LBBB features are present in the ECG, the delay 
in the left bundle conduction must be significant enough 
and residual conduction might not play any important role 
in alleviating the delay of the activation of the lateral LV wall. 
Moreover, an R wave ≥ 1 mm in V1 and/or Q ≥ 1 mm in aVL 
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might be related to the residual conduction in the left septal 
fascicle only (no conduction in the left anterior and posterior 
fascicles of the left bundle branch). Such a situation prob-
ably results in the asynchronous activation of the LV, similar 
to the activation seen in complete LBBB (when LV is also 
activated from the interventricular septum via breakthrough 
points from the right ventricular depolarisation). Therefore, 
despite some residual left bundle conduction, the asynchrony 
might be large enough to warrant CRT and relate to a better 
prognosis post CRT. If this is the case, then the exclusion of 
Figure 2. Kaplan-Meier survival curves for two endpoints: all-cause mortality and the combination of all-cause mortality and 
hospitalisation for heart failure (HF) with regard to the two different definitions of left bundle branch block (LBBB; Perrin and 
Strauss) and the European Society of Cardiology (ESC) guidelines class I (level of evidence A) for cardiac resynchronisation therapy
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Table 3. Multivariate Cox regression models for all-cause mortality in patients with and without left bundle branch block (LBBB) 
according to the Perrin and Strauss definitions and the European Society of Cardiology (ESC) guidelines QRS morphology criteria 
for cardiac resynchronisation therapy (CRT) class I indications with regard to potential confounding variables
HR (95% CI)
Perrin Strauss ESC CRT guidelines
LBBB 0.67* (0.48–0.95) 0.51** (0.38–0.69) 0.73* (0.56–0.96) 
Age 60–70 years 1.02 (0.70–1.50) 0.88 (0.59–1.29) 0.99 (0.68–1.45)
Age > 70 years 1.36 (0.94–1.97) 1.20 (0.82–1.74) 1.31 (0.90–1.90)
Male sex 1.05 (0.72–1.53) 1.04 (0.71–1.52) 1.05 (0.72–1.54)
Ischaemic aetiology 1.34* (0.99–1.82) 1.31 (0.96–1.77) 1.35 (1.00–1.83)
NYHA III 1.82 (0.89–3.72) 1.90 (0.93–3.90) 1.88 (0.92–3.84)
NYHA IV 4.30** (2.00–9.21) 4.63** (2.16–9.92) 4.54** (2.12–9.72)
Permanent AF 0.83 (0.61–1.12) 0.73 * (0.54–1.00) 0.78 (0.57–1.07)
LVEF 20%–30% 0.75 (0.56–1.01) 0.75 (0.55–1.01) 0.76 (0.56–1.02)
LVEF > 30% 0.61* (0.40–0.95) 0.56* (0.36–0.87) 0.58* (0.38–0.90)
LVEDD 60–70 mm 0.76 (0.51–1.12) 0.75 (0.50–1.10) 0.75 (0.51–1.10)
LVEDD > 70 mm 0.82 (0.55–1.23) 0.84 (0.56–1.24) 0.83 (0.56–1.23)
Diabetes mellitus 1.24 (0.95–1.62) 1.27 (0.97–1.66) 1.22 (0.93–1.59)
Creatinine 80–100 µmol/L 1.10 (0.73–1.64) 1.07 (0.72–1.61) 1.10 (0.73–1.65)
Creatinine 101–120 µmol/L 1.07 (0.72–1.60) 0.99 (0.64–1.52) 1.06 (0.69–1.63)
Creatinine > 120 µmol/L 1.30 (0.87–1.96) 1.25 (0.83–1.88) 1.32 (0.88–1.98)
*p < 0.05; **p < 0.01; CI — confidence interval; HR — hazard ratio; other abbreviations — see Table 2
Table 4. Multivariate Cox regression models for the combined endpoint of all-cause mortality and heart failure hospitalisations 
in patients with and without left bundle branch block (LBBB) according to the Perrin and Strauss definitions and the European 
Society of Cardiology (ESC) guidelines QRS morphology criteria for cardiac resynchronisation therapy (CRT) class I indications with 
regard to potential confounding variables
HR (95% CI)
Perrin Strauss ESC CRT guidelines
LBBB 0.58** (0.43–0.79) 0.50** (0.38–0.66) 0.68* (0.53–0.88)   
Age 60–70 years 0.98 (0.71–1.37) 0.83 (0.59–1.17) 0.95 (0.68–1.33)
Age > 70 years 1.07 (0.77–1.48) 0.92 (0.66–1.28) 1.02 (0.74–1.41)
Male sex 0.94 (0.68–1.30) 0.93 (0.67–1.29) 0.95 (0.68–1.31)
Ischaemic aetiology 1.15 (0.88–1.49) 1.12 (0.86–1.46) 1.16 (0.89–1.51)
NYHA III 1.52 (0.86–2.68) 1.62 (0.92–2.85) 1.58 (0.90–2.79)
NYHA IV 2.90** (1.56–5.40) 3.18** (1.71–5.91) 3.11** (1.67–5.79)
Permanent AF 1.03 (0.79–1.34) 0.92 (0.70–1.21) 0.97 (0.74–1.27)
LVEF 20%–30% 0.79 (0.61–1.04) 0.80 (0.62–1.05) 0.81 (0.62–1.05)
LVEF > 30% 0.68 (0.47–1.00) 0.64* (0.44–0.94) 0.65* (0.45–0.96)
LVEDD 60–70 mm 0.81 (0.58–1.15) 0.81 (0.57–1.15) 0.81 (0.57–1.14)
LVEDD > 70 mm 0.86 (0.60–1.22) 0.88 (0.61–1.25) 0.87 (0.61–1.24)
Diabetes mellitus 1.34* (1.06–1.70) 1.35* (1.07–1.71) 1.32* (1.04–1.67)
Creatinine 80–100 µmol/L 1.04 (0.73–1.48) 1.05 (0.74–1.49) 1.07 (0.75–1.52)
Creatinine 100–120 µmol/L 1.05 (0.72–1.53) 0.99 (0.68–1.44) 1.05 (0.72–1.54)
Creatinine > 120 µmol/L 1.34 (0.94–1.93) 1.32 (0.92–1.90) 1.37 (0.95–1.97)
*p < 0.05; **p < 0.01; abbreviations — see Tables 2 and 3
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patients with an R wave ≥ 1 mm in V1, despite other features 
pointing to a true LBBB (notches, QRS duration), results in the 
inclusion of good CRT responders into the non-LBBB group 
and hence the small difference in mortality between LBBB and 
non-LBBB subgroups — as was observed in the current study. 
We have previously assessed the prognostic value of the 
Strauss definition and compared it with three other LBBB defi-
nitions [13]. That study showed the superiority of the Strauss 
definition over the conventional, Marriott and WHO/AHA 
definitions of LBBB [13]. However, in that study we did not 
assess the new Perrin definition and we failed to compare 
these definitions with the QRS morphology fulfilling the high-
est level of indications for CRT according to the recognised 
guidelines. Some studies suggest that QRS duration is more im-
portant than QRS morphology (i.e. LBBB vs. non-LBBB) [11]. 
The CRT guidelines on QRS morphology criteria for class I/ 
/level of evidence A potentially combine the “best of both 
worlds” — both LBBB morphology criteria and QRS duration 
criteria. However, such QRS morphology criteria were never 
compared against new, stricter LBBB definitions. These is-
sues were addressed in the current study: the completion of 
the ESC CRT guideline QRS criteria was found to be inferior 
to fulfilment of the refined LBBB morphology criteria alone 
(Strauss definition). This suggests that the QRS duration is less 
important than the diagnosis of a complete LBBB. Similarly, 
compliance with the Perrin “true LBBB” criteria did not sur-
pass the completion of the “complete LBBB” definition by 
Strauss. The only other study that assessed the “true LBBB” 
definition was the analysis performed on the patients included 
in the PREDICT study by Perrin et al. [18]. In that analysis, 
only a three-month echocardiographic response was assessed; 
therefore, it is not directly comparable with the current study, 
which, for the first time, assessed the prognostic value of these 
criteria with regard to the “hard endpoint” of mortality and 
morbidity, had a much longer follow-up, and was based on 
a much larger cohort (552 vs. 40 patients). However, the per-
centage of LBBB/NIVCD patients in whom “true LBBB” criteria 
were fulfilled was similar in both studies: 30% in the study by 
Perrin et al. [18] vs. 34% in the current study. This points to 
a similar ECG assessment methodology, the exclusive nature 
of these criteria, and the comparability of the studied groups.
The strengths of our study include the large sample size 
of the analysed patients, the availability of complete medical 
data and ECG recordings for almost all participants, and the 
long follow-up period. The sizable number of patients meeting 
the primary endpoint, with lack of cases whose status could 
not be determined, ensures the reliability of mortality data. 
The limitations are typical for any type of retrospective, longi-
tudinal, single-centre cohort study. There is a possibility of the 
presence of unmeasured confounding variables not accounted 
for during this investigation. The single-centre design could 
lead to the possibility of the introduction of treatment bias, 
which could have influenced the outcome of the CRT. The 
patient cohort evaluated in the present study were comparable 
to cohorts in other large studies assessing the outcomes of CRT, 
increasing the reliability of the presented results. Devices were 
implanted using standard approaches by several experienced 
electrophysiologists and the mortality rates were within the 
expected range for patients predominantly in New York Heart 
Association class III. 
In conclusion, it seems that the “true LBBB” criteria pro-
posed by Perrin et al. [18] are not well-suited for the selection 
of CRT candidates, due to the fact they do not reflect the 
presence of a true LBBB. The results of this study add further 
evidence to the fact that the new LBBB definition proposed 
by Strauss is superior to other QRS morphological criteria in 
identifying good CRT responders. This is possibly related to 
better identification of patients with complete LBBB or a sig-
nificant delay of the left ventricular free wall that is correctable 
with biventricular pacing. 
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